Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Apr;7(1):8-18.
doi: 10.2174/157489112799829765.

Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents

Aswani D Vadlapudi  1 , Ramya K Vadlapatla, Ashim K Mitra
Affiliations
Review

Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents

Aswani D Vadlapudi et al. Recent Pat Antiinfect Drug Discov. 2012 Apr.

Abstract

Cytomegalovirus (CMV) retinitis is the most common ocular opportunistic complication and a serious cause of vision loss in immunocompromised patients. Even though, a rise in human immunodeficiency virus (HIV) infected individuals seems to be a major factor responsible for the prevalence of CMV retinitis, the introduction of highly active antiretroviral therapy (HAART) significantly reduced the incidence and severity of CMV retinitis. Thorough evaluation of the patient's immune status and an exact classification of the retinal lesions may provide better understanding of the disease etiology, which would be necessary for optimizing the treatment conditions. Current drugs such as ganciclovir, valganciclovir, cidofovir and foscarnet have been highly active against CMV, but prolonged therapy with these approved drugs is associated with dose-limiting toxicities thus limiting their utility. Moreover development of drug-resistant mutants has been observed particularly in patients with acquired immunodeficiency syndrome (AIDS). Continuous efforts by researchers in the industry and academia have led to the development of newer candidates with enhanced antiviral efficacy and apparently minimal side effects. These novel compounds can suppress viral replication and prevent reactivation in the target population. Though some of the novel therapeutics possess potent viral inhibitory activity, these compounds are still in stages of clinical development and yet to be approved. This review provides an overview of disease etiology, existing anti-CMV drugs, advances in emerging therapeutics in clinical development and related recent patents for the treatment of CMV retinitis.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Characteristics of CMV retinitis (Reproduced with permission from (1)).
Fig. (2)
Fig. (2)
Depiction of the three anatomical zones for classification of CMV retinitis.
Fig. (3)
Fig. (3)
Structures of currently marketed anti-CMV drugs.
Fig. (4)
Fig. (4)
Structures of anti-CMV drugs currently in clinical development.
See this image and copyright information in PMC

References

    1. Heiden D, Ford N, Wilson D, Rodriguez WR, Margolis T, Janssens B, et al. Cytomegalovirus Retinitis: The Neglected Disease of the AIDS Pandemic. PLoS Med. 2007;4(12):e334. - PMC - PubMed
    1. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71(2-3):154–63. - PubMed
    1. Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis. 2000;2(3):112–7. - PubMed
    1. Britt WJ, Mach M. Human Cytomegalovirus Glycoproteins. Intervirology. 1996;39(5-6):401–12. - PubMed
    1. McGavran MH, Smith MG. Ultrastructural, cytochemical, and microchemical observations on cytomegalovirus (salivary gland virus) infection of human cells in tissue culture. Exp Mol Pathol. 1965;76:1–10. - PubMed

Publication types

MeSH terms